Cantos is on record against 38 companies.
Cantos has one venture fund vehicle on file with the SEC, run from San Francisco, California, first sale in 2026. Together they have taken in $3,049,997 from 7 investor positions, most recently on September 4, 2026. The smallest investment it will accept is $100,000.
Cantos is an early-stage venture firm that positions itself as a first-money-in partner for technically ambitious founders working to transform the physical world. The firm's stated focus spans sectors including energy, defense, infrastructure, space, and advanced manufacturing, with a deliberate appetite for underwriting high technical and regulatory risk at the earliest stages of company formation. The firm's portfolio reflects this orientation across a broad range of hard-technology and science-driven ventures. Companies such as Opus 12, Solugen, and Visolis point to a sustained interest in novel chemistry and materials. Dusty Robotics, ALICE Technologies, and Standard Cyborg suggest engagement with robotics and physical automation. SkyRyse and Interstellar indicate exposure to aerospace and next-generation aviation. Prellis Biologics extends the portfolio into advanced biological manufacturing. Arable and AgriData reflect attention to agricultural technology, while Stronghold and Patch signal interest in energy and climate infrastructure. Alongside these deep-technology bets, Cantos has also backed fintech and data infrastructure companies including Dharma Labs, Qwil, Ethic, and Shipamax, as well as health-focused ventures such as Helium Health and Ava, suggesting a founder-first orientation that occasionally follows exceptional technical teams across adjacent domains. Taken together, the portfolio reveals a firm that prioritizes scientific and engineering ambition, backs founders confronting complex regulatory and technical barriers, and seeks to engage at the earliest possible moment in a company's development.